[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.30. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1984

Hematoporphyrin Derivative Photoradiation Therapy in Managing Nevoid Basal-Cell Carcinoma SyndromeA Preliminary Report

Author Affiliations

From the Division of Oculoplastics, Orbital and Oncology Services, Department of Ophthalmology, University of Iowa Hospitals and Clinics, Iowa City.

Arch Ophthalmol. 1984;102(7):990-994. doi:10.1001/archopht.1984.01040030792018
Abstract

• Hematoporphyrin derivative (HpD) is a photodynamically active dye that is preferentially retained by malignant tissues and initiates a cytotoxic reaction when exposed to red light. Normal tissues adjacent to a tumor retain HpD to a lesser degree and are thus spared damage from the light-induced reaction. We describe the treatment of 40 basal-cell carcinomas in three patients with nevoid basal-cell carcinoma syndrome. All treated lesions showed disappearance of clinically apparent tumor within four to six weeks, and there was no damage to surrounding skin. Thirty-three lesions (82.5%) showed complete response on biopsy findings, while seven showed residual tumor cells. The recurrence rate was 10.8%, with the follow-up ranging from 12 to 14 months. Tumor response was related to the total light dose delivered and the size and location of the tumor.

×